Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Opens Up: Can Industry Live With Greater Transparency?

Jul 01 2010

• By Kate Rawson

Related Content

A New Phase for Phase IV: Post-marketing Studies Won't Be the Same After Drug Safety Bill

Oct 01 2007

Avandia and the Commercial Impact of FDA's Credibility Gap

Sep 01 2007

The FDA Roundtable Part I: The Regulators' View of Drug Development

Sep 01 2008

Tracking Troubled NDAs: New FDA Regs Mean Less Clarity for Investors

Jul 01 2008

Transparency in Action: FDA Comments on Pirfenidone

Jul 01 2010

The Avandia Re-Review: Three Scenarios

Jun 01 2010

Opening Up the Black Box: FDA Wants To Make "Complete Response" Letters Public

Jan 01 2010

Related Companies

GSK plc

Pfizer Inc.

Additional Topics

Regulation BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window